Elevated Neutrophil-to-Lymphocyte-ratio and Platelet-to-Lymphocyte Ratio in Myelofibrosis: Inflammatory Biomarkers or Representatives of Myeloproliferation Itself?

Anticancer Res. 2018 May;38(5):3157-3163. doi: 10.21873/anticanres.12579.

Abstract

Background/aim: We aimed to investigate clinical associations of inflammatory biomarkers neutrophil-to-lymphocyte-ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in patients with myelofibrosis, myeloproliferative neoplasm with inflammatory background.

Patients and methods: We retrospectively analyzed a cohort of 102 myelofibrosis patients. NLR and PLR were assessed in addition to other disease-specific parameters.

Results: NLR and PLR were significantly higher in myelofibrosis than in healthy controls. Higher NLR was significantly associated with Janus-kinase-2 (JAK2)-mutation, wild-type-Calreticulin (CALR), older age and parameters reflecting increased proliferative potential of disease (higher leukocytes, higher hemoglobin, larger spleen-size), whereas there was no significant association with C-reactive-protein (CRP). Higher PLR was significantly associated with absence of blast-phase-disease, absence of constitutional-symptoms, lower percentage-of-circulatory-blasts, smaller spleen-size and lower CRP. In the Cox-regression-model, higher-NLR (HR=2.76; p=0.004), lower-PLR (HR=1.99; p=0.042) and Dynamic-International-Prognostic-System (DIPSS) (HR=3.26; p<0.001) predicted inferior survival independently of each other.

Conclusion: In the context of myelofibrosis, elevated NLR and PLR are more likely to represent myeloproliferation itself and not necessary the extent of inflammation.

Keywords: Philadelphia chromosome negative myeloproliferative neoplasm; inflammatory biomarkers; primary myelofibrosis; secondary myelofibrosis; survival.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood*
  • Cohort Studies
  • Female
  • Humans
  • Inflammation / pathology
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Neutrophils
  • Platelet Count
  • Primary Myelofibrosis / blood*
  • Primary Myelofibrosis / pathology*
  • Retrospective Studies

Substances

  • Biomarkers, Tumor